Evaluation of a selective 5-hydroxytryptamine 2B receptor antagonist designed to alter the fibrotic process

Conclusions: The results suggest that the 5-HT2B receptor antagonist AM1125 attenuates lung fibrosis by targeting matrix-producing myofibroblasts. In addition, AM1125 significantly decreases TNF-α production. Altogether, highly selective 5-HT2B receptor antagonists, exemplified by AM1125, represent a new treatment opportunity for lung fibrosis.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway Pharmacology and Treatment Source Type: research